WO2001053456A3 - Methods and materials relating to prothrombinase-like polypeptides and polynucleotides - Google Patents

Methods and materials relating to prothrombinase-like polypeptides and polynucleotides Download PDF

Info

Publication number
WO2001053456A3
WO2001053456A3 PCT/US2000/035061 US0035061W WO0153456A3 WO 2001053456 A3 WO2001053456 A3 WO 2001053456A3 US 0035061 W US0035061 W US 0035061W WO 0153456 A3 WO0153456 A3 WO 0153456A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotides
polypeptides
prothrombinase
methods
seq
Prior art date
Application number
PCT/US2000/035061
Other languages
French (fr)
Other versions
WO2001053456A9 (en
WO2001053456A8 (en
WO2001053456A2 (en
Inventor
Dana A Haley
Bryan J Boyle
Ho Alice Suk-Yue
Ping Zhou
Nancy K Mize
Chiauyun Kuo
Matthew C Arterburn
Y Tom Tang
Chenghua Liu
Radoje Drmanac
Original Assignee
Hyseq Inc
Dana A Haley
Bryan J Boyle
Suk Yue Ho Alice
Ping Zhou
Nancy K Mize
Chiauyun Kuo
Matthew C Arterburn
Y Tom Tang
Chenghua Liu
Radoje Drmanac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/596,196 external-priority patent/US6586390B1/en
Priority claimed from US09/653,274 external-priority patent/US6635742B1/en
Application filed by Hyseq Inc, Dana A Haley, Bryan J Boyle, Suk Yue Ho Alice, Ping Zhou, Nancy K Mize, Chiauyun Kuo, Matthew C Arterburn, Y Tom Tang, Chenghua Liu, Radoje Drmanac filed Critical Hyseq Inc
Priority to JP2001553917A priority Critical patent/JP2004508804A/en
Priority to CA002395749A priority patent/CA2395749A1/en
Priority to EP00989432A priority patent/EP1240178A4/en
Priority to AU25936/01A priority patent/AU783762B2/en
Priority to US10/311,827 priority patent/US20050175994A1/en
Publication of WO2001053456A2 publication Critical patent/WO2001053456A2/en
Publication of WO2001053456A3 publication Critical patent/WO2001053456A3/en
Publication of WO2001053456A8 publication Critical patent/WO2001053456A8/en
Publication of WO2001053456A9 publication Critical patent/WO2001053456A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The invention provides novel polynucleotides and polypeptides encoded by such polynucleotides and mutants or variants thereof that correspond to a novel secreted prothrombinase-like polypeptide. These polynucleotides comprise nucleic acid sequences isolated from cDNA library from human ovary (Hyseq clone identification numbers 773565 (SEQ ID NO: 1) and 7727065 (SEQ ID NO: 11)). Other aspects of the invention include vectors containing processes for producing novel secreted prothrombinase-like polypeptides, and antibodies specific for such polypeptides.
PCT/US2000/035061 1999-01-20 2000-12-22 Methods and materials relating to prothrombinase-like polypeptides and polynucleotides WO2001053456A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2001553917A JP2004508804A (en) 2000-01-21 2000-12-22 Methods and materials for prothrombinase-like polypeptides and polynucleotides
CA002395749A CA2395749A1 (en) 1999-12-23 2000-12-22 Methods and materials relating to prothrombinase-like polypeptides and polynucleotides
EP00989432A EP1240178A4 (en) 1999-12-23 2000-12-22 Methods and materials relating to prothrombinase-like polypeptides and polynucleotides.
AU25936/01A AU783762B2 (en) 1999-12-23 2000-12-22 Methods and materials relating to prothrombinase-like polypeptides and polynucleotides
US10/311,827 US20050175994A1 (en) 1999-01-20 2000-12-22 Methods and materials relating to prothrombinase-like polypeptides and polynucleotides

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US47127599A 1999-12-23 1999-12-23
US09/471,275 1999-12-23
US48872500A 2000-01-21 2000-01-21
US09/488,725 2000-01-21
US49140400A 2000-01-25 2000-01-25
US09/491,404 2000-01-25
US55231700A 2000-04-25 2000-04-25
US09/552,317 2000-04-25
US09/596,196 2000-06-17
US09/596,196 US6586390B1 (en) 2000-01-21 2000-06-17 Methods and materials relating to novel prothrombinase-like polypeptides and polynucleotides
US64331300A 2000-08-31 2000-08-31
US09/653,274 US6635742B1 (en) 2000-01-25 2000-08-31 Antibodies specific for semaphorin-like polypeptides
US09/643,313 2000-08-31

Publications (4)

Publication Number Publication Date
WO2001053456A2 WO2001053456A2 (en) 2001-07-26
WO2001053456A3 true WO2001053456A3 (en) 2002-05-30
WO2001053456A8 WO2001053456A8 (en) 2002-07-04
WO2001053456A9 WO2001053456A9 (en) 2002-12-05

Family

ID=27560029

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/035061 WO2001053456A2 (en) 1999-01-20 2000-12-22 Methods and materials relating to prothrombinase-like polypeptides and polynucleotides

Country Status (4)

Country Link
EP (1) EP1240178A4 (en)
AU (1) AU783762B2 (en)
CA (1) CA2395749A1 (en)
WO (1) WO2001053456A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002224056A1 (en) * 2000-11-22 2002-06-03 Yamanouchi Pharmaceutical Co..Ltd. Novel polypeptide
WO2003027143A2 (en) 2001-09-25 2003-04-03 Japan As Represented By The President Of The University Of Tokyo Gene and protein relating to hepatocellular carcinoma
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
US20060182755A1 (en) * 2002-09-11 2006-08-17 Genentech, Inc. Novel composition and methods for the treatment of psoriasis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005825A2 (en) * 1999-07-16 2001-01-25 Hyseq, Inc. Nucleic acid sequences encoding putative angiopoietin proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001005825A2 (en) * 1999-07-16 2001-01-25 Hyseq, Inc. Nucleic acid sequences encoding putative angiopoietin proteins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE GENEMBL [online] COMPUGEN LTD.; BALLINGER ET AL.: "Novel angiopoietin materials and methods", XP002944228, accession no. GenCore Database accession no. AX079973 *
DATABASE GENEMBL [online] COMPUGEN LTD.; March 2000 (2000-03-01), BIRREN ET AL.: "Homo sapiens, clone RP11-21G19, direct submission", XP002944227, accession no. GenCore Database accession no. AC015500 *
GALE ET AL.: "Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins and ephrins in vascular development", GENES & DEV., vol. 13, 1999, pages 1055 - 1066, XP002944219 *
LEVY ET AL.: "Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis", AM. J. PATH., vol. 156, no. 4, April 2000 (2000-04-01), pages 1217 - 1225, XP002944220 *
See also references of EP1240178A4 *

Also Published As

Publication number Publication date
EP1240178A2 (en) 2002-09-18
WO2001053456A9 (en) 2002-12-05
WO2001053456A8 (en) 2002-07-04
AU783762B2 (en) 2005-12-01
WO2001053456A2 (en) 2001-07-26
CA2395749A1 (en) 2001-07-26
AU2593601A (en) 2001-07-31
EP1240178A4 (en) 2004-06-30

Similar Documents

Publication Publication Date Title
WO2001088092A3 (en) Methods and materials relating to stem cell factor-like (scf-like) polypeptides and polynucleotides
CA2343715A1 (en) New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
WO2001055336A3 (en) Methods and materials relating to cd84-like polypeptides and polynucleotides
EP1308459A3 (en) Full-length cDNA sequences
WO2001077169A3 (en) Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
CA2318030A1 (en) Acpl dna and polypeptides
WO2001053454A3 (en) Methods and materials relating to g protein-coupled receptor-like polypeptides and polynucleotides
IL141869A0 (en) Mammalian transforming growth factor beta-9 (ztgfss9)
WO2003029405A3 (en) Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides
WO2001055335A3 (en) Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides
EP1574520A3 (en) Methods and materials relating to neuronal guidance molecule-like (NGM-like) polypeptides and polynucleotides
WO2001053456A3 (en) Methods and materials relating to prothrombinase-like polypeptides and polynucleotides
EP0759470A3 (en) Gene encoding endoglycoceramidase activator
WO2001053500A8 (en) Methods and materials relating to stem cell growth factor-like poypeptides and polynucleotides
WO2001075064A3 (en) Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides
WO2001055337A3 (en) Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides
WO2001057233A3 (en) Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides
WO2001055332A3 (en) Methods and materials relating to novel growth regulatory-like polypeptides and polynucleotides
WO2001055435A3 (en) Methods and materials relating to hematopoietic cytokine-like polypeptides and polynucleotides
WO2003040326A3 (en) Methods and materials relating to prokineticin-like polypeptides and polynucleotides
WO2001057175A3 (en) Methods and materials relating to neurotrimin-like polypeptides and polynucleotides
EP0801133A3 (en) Hydroperoxide lyases
WO2000004041A3 (en) Methods and molecules relating to cd39-like polypeptides
WO2001029224A3 (en) Granulocyte peptide homolog zgpa1
WO1997040069A3 (en) Secreted proteins and polynucleotides encoding them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2395749

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000989432

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 553917

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
WWE Wipo information: entry into national phase

Ref document number: 25936/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000989432

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10311827

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 25936/01

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000989432

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)